Clinical aspects of Chagas disease and implications for novel therapies

Drug Development Research

Volumn 72, Issue 6, 2011, Pages 471-479

  Menezes, Cristiane ^a,b   Costa, Germano Carneiro ^c   Gollob, Kenneth J ^b,d,e   Dutra, Walderez O ^b,d,f  

^a FEDERAL UNIVERSITY OF OURO PRETO   (Brazil)

^b National Institute of Science and Technology for Complex Systems   (Brazil)

^c FEDERAL UNIVERSITY OF VIÇOSA   (Brazil)

^d SRI INTERNATIONAL   (United States)

^e Santa Casa Hospital   (Brazil)

^f FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

cardiomyopathy; Chagas disease; pathology; treatment; Trypanosoma cruzi

Indexed keywords

2 [2 (2,4 DIFLUOROPHENYL) 2 HYDROXY 1 METHYL 3 (1H 1,2,4 TRIAZOL 1 YL)PROPYL] 4 [4 (2,2,3,3 TETRAFLUOROPROPOXY)PHENYL] 1,2,4 TRIAZOL 3(2H) ONE; ALBACONAZOLE; ALLOPURINOL; AMIODARONE; ANTITRYPANOSOMAL AGENT; BENZNIDAZOLE; DB 766; E 5700; ER 119884; ITRACONAZOLE; K 777; KETOCONAZOLE; NIFURTIMOX; POSACONAZOLE; RAVUCONAZOLE; UNCLASSIFIED DRUG;

CHAGAS DISEASE; CHILE; ENVIRONMENTAL FACTOR; HOST PARASITE INTERACTION; HUMAN; IMMUNOPATHOGENESIS; INFECTION PREVENTION; KINETOPLAST; PALEOPATHOLOGY; PARASITE CONTROL; PERU; RECOMMENDED DRUG DOSE; REVIEW; TRYPANOSOMA CRUZI;

EID: 80053019897     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.20454     Document Type: Review

References (53)

1. Alarcon de Noya B, Diaz-Bello Z, Colmenares C, Ruiz-Guevara R, Mauriello L, Zavala-Jaspe R, Suarez JA, Abate T, Naranjo L, Paiva M, et al. 2010. Large urban outbreak of orally acquired acute Chagas disease at a school in Caracas, Venezuela. J Infect Dis 201: 1308-1315.
2. Antas PR, Medrano-Mercado N, Torrico F, Ugarte-Fernandez R, Gomez F, Correa Oliveira R, Chaves AC, Romanha AJ, Araujo-Jorge TC,. 1999. Early, intermediate, and late acute stages in Chagas' disease: a study combining anti-galactose IgG, specific serodiagnosis, and polymerase chain reaction analysis. Am J Trop Med Hyg 61: 308-314. (Pubitemid 29380267)
3. Apt W,. 2010. Current and developing therapeutic agents in the treatment of Chagas disease. Drug Des Devel Ther 4: 243-253.
4. Apt W, Aguilera X, Arribada A, Perez C, Miranda C, Sanchez G, Zulantay I, Cortes P, Rodriguez J, Juri D,. 1998. Treatment of chronic Chagas' disease with itraconazole and allopurinol. Am J Trop Med Hyg 59: 133-138. (Pubitemid 28304810)
5. Avila JL, Avila A,. 1981. Trypanosoma cruzi: allopurinol in the treatment of mice with experimental acute Chagas disease. Exp Parasitol 51: 204-208. (Pubitemid 11127252)
6. Barr SC, Warner KL, Kornreic BG, Piscitelli J, Wolfe A, Benet L, McKerrow JH,. 2005. A cysteine protease inhibitor protects dogs from cardiac damage during infection by Trypanosoma cruzi. Antimicrob Agents Chemother 49: 5160-5161. (Pubitemid 41778941)
7. Bastos CJ, Aras R, Mota G, Reis F, Dias JP, de Jesus RS, Freire MS, de Araujo EG, Prazeres J, Grassi MF,. 2010. Clinical outcomes of thirteen patients with acute chagas disease acquired through oral transmission from two urban outbreaks in northeastern Brazil. PLoS Negl Trop Dis 4: e711.
8. Batista Dda G, Batista MM, de Oliveira GM, do Amaral PB, Lannes-Vieira J, Britto CC, Junqueira A, Lima MM, Romanha AJ, Sales Junior PA, et al. 2010. Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment. Antimicrob Agents Chemother 54: 2940-2952.
9. Benaim G, Sanders JM, Garcia-Marchan Y, Colina C, Lira R, Caldera AR, Payares G, Sanoja C, Burgos JM, Leon-Rossell A, et al. 2006. Amiodarone has intrinsic anti-Trypanosoma cruzi activity and acts synergistically with posaconazole. J Med Chem 49: 892-899. (Pubitemid 43221637)
10. Benchimol-Barbosa PR,. 2010. Trends on acute Chagas' disease transmitted by oral route in Brazil: steady increase in new cases and a concealed residual fluctuation. Int J Cardiol 145: 494-496.
11. Bern C, Montgomery SP, Katz L, Caglioti S, Stramer SL,. 2008. Chagas disease and the US blood supply. Curr Opin Infect Dis 21: 476-482.
12. Boiani M, Piacenza L, Hernandez P, Boiani L, Cerecetto H, Gonzalez M, Denicola A,. 2010. Mode of action of nifurtimox and N-oxide-containing heterocycles against Trypanosoma cruzi: is oxidative stress involved? Biochem Pharmacol 79: 1736-1745.
13. Cancado JR,. 2002. Long term evaluation of etiological treatment of chagas disease with benznidazole. Rev Inst Med Trop Sao Paulo 44: 29-37. (Pubitemid 34205107)
14. Cazzulo JJ, Cazzulo Franke MC, Martinez J, Franke de Cazzulo BM,. 1990. Some kinetic properties of a cysteine proteinase (cruzipain) from Trypanosoma cruzi. Biochim Biophys Acta 1037: 186-191. (Pubitemid 20043410)
15. Chiari E,. 1999. Chagas disease diagnosis using polymerase chain reaction, hemoculture and serologic methods. Mem Inst Oswaldo Cruz 94 (Suppl 1): 299-300. (Pubitemid 129584514)
16. Coelho dos Santos JS, Menezes CA, Villani FN, Magalhaes LM, Scharfstein J, Gollob KJ, Dutra WO,. 2010. Captopril increases the intensity of monocyte infection by Trypanosoma cruzi and induces human T helper type 17 cells. Clin Exp Immunol 162: 528-536.
17. Coura JR,. 2009. Present situation and new strategies for Chagas disease chemotherapy: a proposal. Mem Inst Oswaldo Cruz 104: 549-554.
18. Dubner S, Schapachnik E, Riera AR, Valero E,. 2008. Chagas disease: state-of-the-art of diagnosis and management. Cardiol J 15: 493-504.
19. Dutra WO, Gollob KJ,. 2008. Current concepts in immunoregulation and pathology of human Chagas disease. Curr Opin Infect Dis 21: 287-292. (Pubitemid 351620383)
20. Dutra WO, Rocha MO, Teixeira MM,. 2005. The clinical immunology of human Chagas disease. Trends Parasitol 21: 581-587. (Pubitemid 41572271)
21. Dutra WO, Menezes CA, Villani FN, da Costa GC, da Silveira AB, Reis D, Gollob KJ,. 2009. Cellular and genetic mechanisms involved in the generation of protective and pathogenic immune responses in human Chagas disease. Mem Inst Oswaldo Cruz 104 (Suppl 1): 208-218.
22. Espinosa R, Carrasco HA, Belandria F, Fuenmayor AM, Molina C, Gonzalez R, Martinez O,. 1985. Life expectancy analysis in patients with Chagas' disease: prognosis after one decade (1973-1983). Int J Cardiol 8: 45-56. (Pubitemid 15031383)
23. Gurgel CB, Almeida EA,. 2007. Frequency of hypertension in patients with chronic Chagas disease and its consequences on the heart: a clinical and pathological study. Arq Bras Cardiol 89: 174-182; 191-200.
24. Herrera C, Vallejos GA, Loaiza R, Zeledon R, Urbina A, Sepulveda-Boza S,. 2009. In vitro activity of thienyl-2-nitropropene compounds against Trypanosoma cruzi. Mem Inst Oswaldo Cruz 104: 980-985.
25. Hu L, Arafa RK, Ismail MA, Wenzler T, Brun R, Munde M, Wilson WD, Nzimiro S, Samyesudhas S, Werbovetz KA, et al. 2008. Azaterphenyl diamidines as antileishmanial agents. Bioorg Med Chem Lett 18: 247-251.
26. Leon JS, Wang K, Engman DM,. 2003. Captopril ameliorates myocarditis in acute experimental Chagas disease. Circulation 107: 2264-2269. (Pubitemid 36547223)
27. Mady C, Cardoso RH, Barretto AC, da Luz PL, Bellotti G, Pileggi F,. 1994. Survival and predictors of survival in patients with congestive heart failure due to Chagas' cardiomyopathy. Circulation 90: 3098-3102.
28. Marin-Neto JA, Bromberg-Marin G, Pazin-Filho A, Simoes MV, Maciel BC,. 1998. Cardiac autonomic impairment and early myocardial damage involving the right ventricle are independent phenomena in Chagas' disease. Int J Cardiol 65: 261-269. (Pubitemid 28368332)
29. Marin-Neto JA, Rassi A Jr, Avezum A Jr, Mattos AC, Rassi A, Morillo CA, Sosa-Estani S, Yusuf S,. 2009. The BENEFIT trial: testing the hypothesis that trypanocidal therapy is beneficial for patients with chronic Chagas heart disease. Mem Inst Oswaldo Cruz 104 (Suppl 1): 319-324.
30. Maya JD, Cassels BK, Iturriaga-Vasquez P, Ferreira J, Faundez M, Galanti N, Ferreira A, Morello A,. 2007. Mode of action of natural and synthetic drugs against Trypanosoma cruzi and their interaction with the mammalian host. Comp Biochem Physiol A Mol Integr Physiol 146: 601-620. (Pubitemid 46341910)
31. McKerrow JH, Doyle PS, Engel JC, Podust LM, Robertson SA, Ferreira R, Saxton T, Arkin M, Kerr ID, Brinen LS, et al. 2009. Two approaches to discovering and developing new drugs for Chagas disease. Mem Inst Oswaldo Cruz 104 (Suppl 1): 263-269.
32. Molina RB, Matsubara BB, Hueb JC, Zanati SG, Meira DA, Cassolato JL, Paiva SA, Zornoff LA,. 2006. Dysautonomia and ventricular dysfunction in the indeterminate form of Chagas disease. Int J Cardiol 113: 188-193. (Pubitemid 44648402)
33. Morris SA, Tanowitz HB, Wittner M, Bilezikian JP,. 1990. Pathophysiological insights into the cardiomyopathy of Chagas' disease. Circulation 82: 1900-1909.
34. Munoz MJ, Murcia L, Segovia M,. 2011. The urgent need to develop new drugs and tools for the treatment of Chagas disease. Expert Rev Anti Infect Ther 9: 5-7.
35. Pinazo MJ, Munoz J, Posada E, Lopez-Chejade P, Gallego M, Ayala E, del Cacho E, Soy D, Gascon J,. 2010. Tolerance of benznidazole in treatment of Chagas' disease in adults. Antimicrob Agents Chemother 54: 4896-4899.
36. Pinto AY, Ferreira Jr AG, Valente Vda C, Harada GS, Valente SA,. 2009. Urban outbreak of acute Chagas disease in Amazon region of Brazil: four-year follow-up after treatment with benznidazole. Rev Panam Salud Publica 25: 77-83.
37. Prata A,. 2001. Clinical and epidemiological aspects of Chagas disease. Lancet Infect Dis 1: 92-100. (Pubitemid 33586044)
38. Rassi Jr A, Rassi A, Little WC, Xavier SS, Rassi SG, Rassi AG, Rassi GG, Hasslocher-Moreno A, Sousa AS, Scanavacca MI,. 2006. Development and validation of a risk score for predicting death in Chagas' heart disease. N Engl J Med 355: 799-808. (Pubitemid 44285585)
39. Ribeiro AL, Reis AM, Teixeira MM, Rocha MO,. 2003. Brain natriuretic peptide in Chagas' disease: further insights. Lancet 362: 333. (Pubitemid 36936857)
40. Rocha MO, Ribeiro AL, Teixeira MM,. 2003. Clinical management of chronic Chagas cardiomyopathy. Front Biosci 8: e44-e54.
41. Rocha MO, Teixeira MM, Ribeiro AL,. 2007. An update on the management of Chagas cardiomyopathy. Expert Rev Anti Infect Ther 5: 727-743. (Pubitemid 47250142)
42. Silva CF, Batista MM, Mota RA, de Souza EM, Stephens CE, Som P, Boykin DW, Soeiro Mde N,. 2007. Activity of "reversed" diamidines against Trypanosoma cruzi "in vitro. Biochem Pharmacol 73: 1939-1946. (Pubitemid 46677912)
43. Sosa Estani S, Segura EL, Ruiz AM, Velazquez E, Porcel BM, Yampotis C,. 1998. Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas' disease. Am J Trop Med Hyg 59: 526-529. (Pubitemid 28480704)
44. Sosa-Estani S, Viotti R, Segura EL,. 2009. Therapy, diagnosis and prognosis of chronic Chagas disease: insight gained in Argentina. Mem Inst Oswaldo Cruz 104 (Suppl 1): 167-180.
45. Steindel M, Kramer Pacheco L, Scholl D, Soares M, de Moraes MH, Eger I, Kosmann C, Sincero TC, Stoco PH, Murta SM, et al. 2008. Characterization of Trypanosoma cruzi isolated from humans, vectors, and animal reservoirs following an outbreak of acute human Chagas disease in Santa Catarina State, Brazil. Diagn Microbiol Infect Dis 60: 25-32. (Pubitemid 350235169)
46. Urbina JA,. 2002. Chemotherapy of Chagas disease. Curr Pharm Des 8: 287-295. (Pubitemid 34449884)
47. Urbina JA, Concepcion JL, Caldera A, Payares G, Sanoja C, Otomo T, Hiyoshi H,. 2004. In vitro and in vivo activities of E5700 and ER-119884, two novel orally active squalene synthase inhibitors, against Trypanosoma cruzi. Antimicrob Agents Chemother 48: 2379-2387. (Pubitemid 38823400)
48. Urbina JA, Docampo R,. 2003. Specific chemotherapy of Chagas disease: controversies and advances. Trends Parasitol 19: 495-501. (Pubitemid 37329658)
49. Vago AR, Andrade LO, Leite AA, d'Avila Reis D, Macedo AM, Adad SJ, Tostes Jr S, Moreira MC, Filho GB, Pena SD,. 2000. Genetic characterization of Trypanosoma cruzi directly from tissues of patients with chronic Chagas disease: differential distribution of genetic types into diverse organs. Am J Pathol 156: 1805-1809. (Pubitemid 30646718)
50. Viotti R, Vigliano C,. 2007. Etiological treatment of chronic Chagas disease: neglected "evidence" by evidence-based medicine. Expert Rev Anti Infect Ther 5: 717-726. (Pubitemid 47250141)
51. Viotti R, Vigliano C, Lococo B, Bertocchi G, Petti M, Alvarez MG, Postan M, Armenti A,. 2006. Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial. Ann Intern Med 144: 724-734. (Pubitemid 46780632)
52. Viotti R, Vigliano C, Lococo B, Alvarez MG, Petti M, Bertocchi G, Armenti A,. 2009. Side effects of benznidazole as treatment in chronic Chagas disease: fears and realities. Expert Rev Anti Infect Ther 7: 157-163.
53. WHO. 2010. First WHO Report on Neglected Diseases: working to overcome the global impact of neglected tropical diseases.